Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Balding Clear all
Enrolling by invitation Not applicable Interventional

Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

NCT07224555
View directory record Official record
Conditions
Hair Thinning
Interventions
Xtressé Hair Growth Gummies
Other
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Maitland, Florida • Alpharetta, Georgia • Marriottsville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of the Mosaic Ultra Device

NCT06117293
View directory record Official record
Conditions
Skin Texture Disorder, Photoaging, Wrinkle, Scar, Stretch Mark, Acne Vulgaris, Hair Loss
Interventions
Mosaic
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Lincolnshire, Illinois • Billerica, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 30, 2026, 10:40 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT06747611
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Vancomycin, Neomycin and MTT capsules, Placebo capsules
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

NCT01367990
View directory record Official record
Conditions
Alopecia, Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 30, 2026, 10:40 PM EDT
Active, not recruiting Not applicable Interventional

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

NCT04180579
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
PAXMAN Scalp Cooler
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 30, 2026, 10:40 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

AGA Biocellular Stem/Stromal Hair Regenerative Study

NCT02849470
View directory record Official record
Conditions
Hair Disease
Interventions
Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells, Stem/Stromal Cellular Isolation (Digestive), MatriStem Matrix (ACell) - Current Standard of Care, HD-PRP (High Density Platelet Rich Plasma), Emulsified AD-tSVF, Emulsified AD-cSVF
Procedure
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

NCT04409041
View directory record Official record
Conditions
Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Low-Dose Naltrexone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 30, 2026, 10:40 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 10:40 PM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

NCT03359356
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

NCT06149221
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
NTAP
Device
Lead sponsor
Dr. Peter C. Friedman
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT00484679
View directory record Official record
Conditions
Alopecia Areata
Interventions
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

NCT02503137
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05914805
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Results available

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

NCT01588522
View directory record Official record
Conditions
Chemotherapy-Induced Alopecia
Interventions
Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL, Compound 31543 Calcitriol 40 μg/mL, Compound 31543 Calcitriol 60 ug/mL, Compound 31543 Calcitriol 80 μg/mL
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

NCT01385839
View directory record Official record
Conditions
Alopecia Areata, Alopecia, Balding
Interventions
Hair transplantation, Hypodermic needle irritation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)

NCT01451177
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Los Angeles, California • Las Vegas, Nevada • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 30, 2026, 10:40 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06602232
View directory record Official record
Conditions
Alopecia Areata, Vitiligo
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Northridge, California • Miami, Florida • Evans, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428
View directory record Official record
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2006 · Synced Oct 30, 2026, 10:40 PM EDT
Recruiting Not applicable Interventional

The Lily Device Trial

NCT06786078
View directory record Official record
Conditions
Chemotherapy Induced Alopecia
Interventions
Lily Device
Device
Lead sponsor
Luminate Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Mullica Hill, New Jersey • Vineland, New Jersey • Binghamton, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 30, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

NCT06112782
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Keravive by Hydrafacial Treatments
Device
Lead sponsor
Beauty Health
Industry
Eligibility
30 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 30, 2026, 10:40 PM EDT